Kalvista Pharmaceuticals Inc (KALV)
Official siteBIOTECHNOLOGY
Last updated: Jun 12, 2026 at 5:00 PM ET
Kalvista Pharmaceuticals Inc (KALV) Financials: Revenue, Profit and Cash Flow
Kalvista Pharmaceuticals reported revenue of $73.62M for the fiscal year ended Apr 30, 2026. That year, net income was -$164.29M with a net margin of -223.2%, operating cash flow was -$81.62M and free cash flow was -$83.33M. The quarter ended Apr 30, 2026 had revenue of $59.92M and net income of -$5.37M.
Revenue and Margins
Over the 9 years to Apr 2026, revenue grew from $1.50M, a compound annual rate of 54.1%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Apr 2026 | $73.62M | N/A | 91.7% | -233.4% | -223.2% |
| Apr 2025 | $0 | N/A | N/A | N/A | N/A |
| Apr 2024 | $0 | N/A | N/A | N/A | N/A |
| Apr 2023 | $0 | N/A | N/A | N/A | N/A |
| Apr 2022 | $0 | -100.0% | N/A | N/A | N/A |
| Apr 2021 | $12.69M | 0.0% | -325.3% | -456.4% | -364.4% |
| Apr 2020 | $12.69M | -21.3% | -216.7% | -319.4% | -229.4% |
| Apr 2019 | $16.13M | +92.1% | 99.8% | -184.9% | -129.1% |
| Apr 2018 | $8.39M | +458.1% | 99.8% | -222.8% | -188.3% |
| Apr 2017 | $1.50M | N/A | 99.2% | -1485.3% | -1236.9% |
Income Statement
In the fiscal year ended Apr 2026, the net loss narrowed from the year before. In the quarter ended Apr 2026, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 | Apr 2021 | Apr 2020 | Apr 2019 | Apr 2018 | Apr 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $73.62M | $0 | $0 | $0 | $0 | $12.69M | $12.69M | $16.13M | $8.39M | $1.50M |
| Cost of revenue | $6.08M | $941.00K | $86.17M | $802.00K | $743.00K | $41.29M | $40.19M | $35.02K | $18.24K | $12.67K |
| Gross profit | $67.54M | -$941.00K | -$86.17M | -$802.00K | -$743.00K | -$41.29M | -$27.50M | $16.09M | $8.38M | $1.49M |
| Research and development | $55.64M | $71.71M | $86.17M | $80.28M | $70.17M | $41.29M | $40.19M | $35.02M | $18.24M | $12.67M |
| Operating income | -$171.84M | -$188.00M | -$140.44M | -$110.87M | -$96.61M | -$57.92M | -$40.53M | -$29.82M | -$18.70M | -$22.34M |
| Net income | -$164.29M | -$183.44M | -$126.64M | -$92.91M | -$82.34M | -$46.24M | -$29.12M | -$20.82M | -$15.80M | -$18.60M |
| EBITDA | -$150.62M | -$173.33M | -$134.28M | -$94.37M | -$80.75M | -$57.39M | -$40.02M | -$29.44M | -$18.52M | -$22.30M |
Quarterly
| Line item | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | Oct 2023 | Jul 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $59.92M | $40.86M | $40.86M | $1.43M | $0 | $0 | $0 | $0 | $1.21M | $0 | $0 | $0 |
| Gross profit | $55.95M | $37.77M | $37.42M | $836.00K | -$15.89M | N/A | N/A | -$224.00K | -$25.25M | -$207.00K | -$19.09M | -$19.31M |
| Operating income | -$11.51M | -$23.44M | -$23.44M | -$59.01M | -$55.03M | -$42.94M | -$45.81M | -$44.22M | -$48.45M | -$33.15M | -$29.75M | -$29.09M |
| Net income | -$5.37M | -$23.49M | -$23.49M | -$60.10M | -$52.23M | -$48.51M | -$42.27M | -$40.44M | -$44.65M | -$29.03M | -$27.65M | -$25.32M |
Balance Sheet
As of Apr 2026, cash and equivalents exceeded total debt of $140.85M by $88.49M. Shareholder equity was negative, at -$2.71M, as total liabilities of $338.09M exceeded total assets of $335.38M.
Annual
| Line item | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 | Apr 2021 | Apr 2020 | Apr 2019 | Apr 2018 | Apr 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $335.38M | $250.77M | $235.40M | $183.20M | $203.88M | $272.01M | $92.53M | $118.13M | $61.39M | $34.34M |
| Current assets | $320.15M | $241.69M | $225.69M | $172.33M | $193.65M | $264.26M | $88.70M | $115.55M | $59.38M | $34.25M |
| Cash and equivalents | $229.34M | $98.64M | $31.79M | $56.24M | $30.73M | $50.59M | $15.79M | $32.01M | $51.05M | $30.95M |
| Total liabilities | $338.09M | $155.38M | $28.82M | $22.18M | $18.79M | $14.82M | $8.78M | $21.39M | $34.14M | $3.02M |
| Short-term debt | $1.62M | $1.98M | $1.30M | $1.09M | $977.00K | $863.00K | $588.00K | $54.00K | $221.00K | N/A |
| Long-term debt | $139.23M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $58.00K | $0 |
| Shareholder equity | -$2.71M | $95.39M | $206.58M | $161.03M | $185.09M | $257.19M | $83.75M | $96.74M | $27.25M | $31.33M |
Quarterly
| Line item | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | Oct 2023 | Jul 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $335.38M | $328.92M | $335.38M | $215.50M | $250.77M | $275.99M | $160.83M | $200.20M | $235.40M | $113.97M | $138.74M | $160.33M |
| Total liabilities | $338.09M | $348.57M | $338.09M | $174.72M | $155.38M | $130.87M | $26.84M | $27.40M | $28.82M | $25.39M | $24.30M | $21.00M |
| Cash and equivalents | $229.34M | $213.77M | $229.34M | $124.30M | $98.64M | $167.29M | $41.58M | $31.85M | $31.79M | $23.06M | $57.67M | $49.41M |
| Shareholder equity | -$2.71M | -$19.65M | -$2.71M | $40.79M | $95.39M | $145.13M | $133.99M | $172.80M | $206.58M | $88.58M | $114.45M | $139.34M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Apr 2026.
Annual
| Line item | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 | Apr 2021 | Apr 2020 | Apr 2019 | Apr 2018 | Apr 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$81.62M | -$152.91M | -$89.23M | -$75.26M | -$78.13M | -$30.17M | -$44.82M | -$36.37M | $10.56M | -$23.72M |
| Capital expenditures | $1.71M | $434.00K | $443.00K | $1.20M | $931.00K | $82.00K | $220.00K | $1.08M | $1.43M | $74.00K |
| Free cash flow | -$83.33M | -$153.34M | -$89.67M | -$76.46M | -$79.06M | -$30.25M | -$45.04M | -$37.45M | $9.13M | -$23.80M |
| Investing cash flow | $18.68M | $91.02M | -$84.72M | $41.41M | $57.86M | -$147.65M | $16.75M | -$69.42M | -$1.43M | $34.06M |
| Financing cash flow | $162.64M | $159.73M | $150.71M | $58.12M | $1.58M | $212.12M | $11.58M | $87.94M | $8.99M | $2.00K |
Quarterly
| Line item | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | Oct 2023 | Jul 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $45.36M | -$14.46M | -$14.46M | -$54.50M | -$40.36M | -$32.68M | -$39.64M | -$40.22M | -$15.11M | -$27.57M | -$19.82M | -$26.73M |
| Capital expenditures | $156.00K | $203.00K | $121.00K | $290.00K | $350.00K | $127.00K | $108.00K | $21.00K | $122.00K | $19.00K | $2.00K | $6.00K |
| Free cash flow | $45.21M | -$14.66M | -$14.58M | -$54.79M | -$40.71M | -$32.81M | -$39.75M | -$40.24M | -$15.23M | -$27.59M | -$19.83M | -$26.74M |
Frequently Asked Questions About KALV
What is Kalvista Pharmaceuticals' annual revenue?
Kalvista Pharmaceuticals reported revenue of $73.62M for the fiscal year ended Apr 30, 2026.
Is Kalvista Pharmaceuticals profitable?
No. Kalvista Pharmaceuticals reported net income of -$164.29M for the fiscal year ended Apr 30, 2026, with a net margin of -223.2%.
How much free cash flow does KALV generate?
For the fiscal year ended Apr 30, 2026, operating cash flow of -$81.62M minus capital expenditures of $1.71M produced free cash flow of -$83.33M.
How much debt does Kalvista Pharmaceuticals have?
The balance sheet dated Apr 30, 2026 reported long-term debt of $139.23M, short-term debt of $1.62M and cash and equivalents of $229.34M.
What is KALV's profit margin?
For the fiscal year ended Apr 30, 2026, Kalvista Pharmaceuticals reported gross margin of 91.7%, operating margin of -233.4% and net margin of -223.2%.
KALV pages: Overview, Financials